Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA food imports

This article was originally published in The Tan Sheet

Executive Summary

FDA and Bureau of Customs & Border Protection (CBP) are streamlining implementation of prior notice requirements so food, supplement firms will only have to submit prior notices about import contents to CBP, instead of submitting same information to both agencies, FDA announces May 27. Agencies "have worked together to find ways to modify" CBP's Automated Commercial System, which currently collects import information required by Customs. By December, when prior notice bioterrorism reg must be implemented, ACS will be ready for use solely for prior notice data collection, FDA 1press release states. Issued in February, prior notice proposed rule will require information such as food purchaser's name and address, country of origin, date and time of arrival (2"The Tan Sheet" Feb. 3, 2003, p. 4)...

You may also be interested in...



Food Import Prior Notice Proposed Rule Allows Amendments, Not Appeals

An integrated FDA and U.S. Customs Service food import database should be in place by 2005, the agency says in a 1proposed rule on the prior notification of imported foods

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel